Generated by AI
Rafael Holdings Inc. Class B Common Stock is an equity security representing ownership in Rafael Holdings, a company focused on healthcare-related investments and operations. The company is primarily involved in clinical and early-stage pharmaceutical interests, including oncology-oriented drug development, as well as medical devices and infusion technology activities. Its current business is organized across Healthcare, Infusion Technology, and Real Estate segments, giving it exposure to both life sciences and commercial property assets. Rafael Holdings also holds interests in companies working on therapies that target metabolic differences between normal and cancer cells, which places it within the specialized biopharmaceutical landscape. Headquartered in Newark, New Jersey, Rafael Holdings serves as a publicly traded vehicle for investors seeking exposure to a diversified mix of healthcare innovation and real estate holdings.
Website520 Broad Street
Newark, NJ, 07102
United States
The latest articles about RFL.
Rafael Holdings (NYSE: RFL) stock tumbles after its Phase 3 TransportNPC study of Trappsol Cyclo misses its primary endpoint.
Rafael Holdings Inc Class B (NYSE:RFL) shares fell 25% in pre-market trading on Wednesday after the company’s Phase 3 TransportNPC trial of Trappsol Cyclo in patients with Niemann-Pick Disease Type C (NPC) failed to meet its primary endpoint. The study enrolled 94 patients and evaluated the change from baseline in the 4-domain NPC Clinical Severity Scale at Week 96.
Summary of Oct 29's posts. Generated by AI.
Summary of Jul 1's posts. Generated by AI.
Summary of Sep 30's posts. Generated by AI.
Investors talking about RFL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.